Welcome to our dedicated page for Lilly Eli & Co news (Ticker: LLY), a resource for investors and traders seeking the latest updates and insights on Lilly Eli & Co stock.
Eli Lilly and Company (NYSE: LLY) generates frequent news across cardiometabolic health, oncology, immunology, obesity and manufacturing expansion. This page aggregates recent press releases and third-party coverage so readers can follow how Lilly’s medicines, clinical programs and corporate actions are evolving over time.
Recent updates show Lilly reporting Phase 3 results for multiple late-stage assets. In obesity and cardiometabolic health, the company has shared topline data from ATTAIN-MAINTAIN, a Phase 3 trial of orforglipron, an investigational once-daily oral GLP-1 receptor agonist, for weight maintenance after prior treatment with injectable incretin therapies. Lilly has also reported results from TRIUMPH-4, a Phase 3 trial of retatrutide, an investigational triple agonist targeting GIP, GLP-1 and glucagon receptors, in adults with obesity or overweight and knee osteoarthritis, with co-primary endpoints in weight loss and pain reduction.
In immunology, Lilly has announced positive topline results from the TOGETHER-PsA Phase 3b trial, which evaluated concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) versus Taltz alone in adults with active psoriatic arthritis and obesity or overweight with at least one weight-related condition. The company reports that the combination met the primary endpoint and all key secondary endpoints, supporting an integrated approach to treating psoriatic arthritis and obesity.
Oncology news includes updated EMBER-3 data for Inluriyo (imlunestrant) as monotherapy and in combination with Verzenio (abemaciclib) in ER-positive, HER2-negative advanced breast cancer, and Phase 3 BRUIN CLL-313 results showing that Jaypirca (pirtobrutinib) significantly reduced the risk of progression or death versus chemoimmunotherapy in treatment-naïve CLL/SLL without 17p deletions.
Corporate and strategic news items cover Lilly’s planned acquisition of Ventyx Biosciences, completion of the Adverum Biotechnologies tender offer, a strategic collaboration with Aktis Oncology, and a major manufacturing investment in a new active pharmaceutical ingredient facility in Huntsville, Alabama. Investors and observers can use this news feed to monitor clinical milestones, regulatory submissions, acquisitions, collaborations, financing activities and manufacturing expansions related to LLY.
Eli Lilly will present data from its Phase 3 EMBER-3 trial for imlunestrant, an oral selective estrogen receptor degrader (SERD), at the San Antonio Breast Cancer Symposium in December 2024. The study evaluates imlunestrant alone and combined with Verzenio in ER+, HER2- advanced breast cancer patients previously treated with endocrine therapy. The company will also share real-world analysis of recurrence risk in HR+, HER2- early breast cancer and present data on its PI3Ka inhibitor programs, including preclinical data for LY4045004 and Phase 1a/b results for LOXO-783.
Eli Lilly (LLY) reported strong Q3 2024 financial results with revenue increasing 20% to $11.44 billion. Excluding olanzapine portfolio revenue, total revenue grew 42%, driven by volume growth from Mounjaro and Zepbound. Q3 2024 EPS increased to $1.07 (reported) and $1.18 (non-GAAP). The company updated its 2024 guidance, projecting revenue of $45.4-$46.0 billion and EPS of $12.05-$12.55 (reported) and $13.02-$13.52 (non-GAAP). Key achievements included FDA approval of Ebglyss for atopic dermatitis and positive Phase 3 data showing 94% reduction in type 2 diabetes risk with tirzepatide.
Eli Lilly announced positive results from the TRAILBLAZER-ALZ 6 Phase 3b study for Kisunla (donanemab) in early symptomatic Alzheimer's disease. A modified titration dosing regimen, which shifted one vial from the first infusion to the third infusion, reduced ARIA-E incidence to 14% compared to 24% with standard dosing. The reduction was most significant in APOE4 homozygotes, dropping from 57% to 19%. The modified regimen maintained comparable amyloid plaque reduction (67% vs 69%) and P-tau217 levels. Lilly plans to submit this data to regulators for a potential label update.
Eli Lilly (NYSE: LLY) has announced its quarterly dividend payment for Q4 2024. The company's board of directors has declared a dividend of $1.30 per share on outstanding common stock. The dividend will be paid on December 10, 2024, to shareholders who are on record as of November 15, 2024.
Eli Lilly announced breakthrough results from two Phase 3 studies demonstrating the long-term effectiveness of mirikizumab in treating inflammatory bowel diseases. The drug showed remarkable success in maintaining remission for patients with ulcerative colitis and Crohn's disease.
After three years, over 80% of ulcerative colitis patients maintained remission and symptom relief. For Crohn's disease patients, more than 50% sustained endoscopic remission for up to five years. Mirikizumab, the first IL23p19 antagonist to report such long-term data, demonstrated a consistent safety profile across both conditions.
The drug is already FDA-approved for ulcerative colitis treatment and is under review for Crohn's disease. These findings were presented at the American College of Gastroenterology Annual Meeting 2024.
Eli Lilly's EBGLYSS (lebrikizumab-lbkz) demonstrated significant efficacy in treating moderate-to-severe atopic dermatitis patients who previously discontinued dupilumab. In the Phase 3b ADapt study, 57% of patients achieved EASI-75 at Week 16, and 60% at Week 24. The treatment showed particular effectiveness in difficult-to-treat areas, with 52% of patients achieving clear or almost clear face dermatitis at Week 24. The drug's safety profile remained consistent with previous studies, with less than 6% of patients discontinuing due to adverse events. EBGLYSS, recently approved by the FDA, is administered as a monthly maintenance injection following an initial treatment phase.
Eli Lilly's Kisunla™ (donanemab) has received marketing authorization in Great Britain for treating mild cognitive impairment and mild dementia due to Alzheimer's disease in specific adult patients. The approval is to apolipoprotein E ε4 heterozygotes or non-carriers. This marks Great Britain as the third major market to approve donanemab, following approvals in the United States (July 2024) and Japan (September 2024). The drug, administered via intravenous infusion every four weeks, is unique as the only amyloid plaque-targeting therapy with evidence supporting treatment discontinuation after plaque removal. In the UK, where an estimated 982,000 people live with dementia, the total cost of dementia care is projected at £42 billion in 2024.
Eli Lilly and Company (NYSE: LLY) has announced that it will release its third-quarter 2024 financial results on October 30, 2024. The company will also host a conference call at 10 a.m. Eastern time on the same day to discuss the financial performance with investors, media, and the general public.
A live webcast of the conference call will be accessible through a link on Lilly's investor relations website. For those unable to attend the live event, a replay will be available on the same website following the conference call.
Eli Lilly and Company released results from their national 'Urgent Conversations' survey, highlighting the challenges faced by people with ulcerative colitis (UC) in finding public restrooms. The survey of 1,800 U.S. adults, including 200 with moderately to severely active UC, found that 84% of UC patients struggle to find public restrooms, compared to 60% of the general population.
Key findings include:
- 63% of UC respondents need to use restrooms frequently when leaving home
- 81% of UC respondents take over 5 minutes to find a clean restroom
- 42% of UC respondents are more likely to have restroom emergencies
- 61% of UC respondents limit social outings due to restroom concerns
The Crohn's & Colitis Foundation has launched the 'We Can't Wait' mobile app to help locate public restrooms. Lilly's Omvoh® (mirikizumab-mrkz), approved in October 2023, showed promising results in treating UC symptoms and improving bowel urgency in clinical trials.
Eli Lilly and Company (NYSE: LLY) announced new data from the VIVID-1 Phase 3 study of mirikizumab for Crohn's disease. The study showed that more patients treated with mirikizumab achieved histologic response at Week 52 compared to ustekinumab, regardless of prior biologic experience. This is the first Phase 3 study to report histologic and combined histologic-endoscopic outcomes in Crohn's disease using a systematic assessment of five bowel segments.
Key findings include:
- 58.2% of mirikizumab patients achieved histologic response at Week 52 vs 48.8% for ustekinumab (p=0.0075)
- In patients with prior biologic failure, 56.5% on mirikizumab achieved histologic response at Week 52 vs 41.3% for ustekinumab (p=0.0064)
- Mirikizumab's safety profile was consistent with its known profile in ulcerative colitis
Lilly has submitted marketing authorization applications for mirikizumab in Crohn's disease globally and is conducting additional studies in pediatric and adult patients.